Healthy adults
Conditions
Interventions
Daily ingestion 17 g of the raw spirulina for 2 weeks.
Daily ingestion 3.5 g of the mix powder containing barley young leaf and euglena for 2 weeks.
Sponsors
Hokkaido Information University
Bioresource and Bioenvironment Kyushu University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Subjects who agree to participate in this study with a written informed consent. 2. Subjects with defecation frequency between minimum 3 to maximum 5 per week. 3. Subjects who are aware of having a tendency toward constipation.
Exclusion criteria
Exclusion criteria: 1. Subjects with a clinical history of gastrointestinal cancer or currently under treatment or anti-tumor medication. 2. Subjects with gastrointestinal disorders such as inflammatory bowel syndrome, irritable bowel syndrome, etc. 3. Subjects with photosensitivity. 4. Subjects who regularly take anticoagulant, antiplatelet medicine, and/or NSAIDs. 5. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities. 6. Subjects with major surgical history relevant to the digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 7. Subjects with unusually high and/or low blood pressure and/or abnormal hematological data. 8. Subjects with severe anemia. 9. Pre- or post-menopausal women complaining of obvious physical changes. 10. Subjects who are at risk of having allergic reactions to drugs or foods especially based on seaweed and gelatin. 11. Subjects who regularly take the food containing spirulina, young barley, euglena and/or chlorella. 12. Subjects who regularly take drugs, functional foods and/or supplements which potentially affect bowel movements. 13. Heavy smokers, alcohol addicts or subjects with disordered lifestyle. 14. Subjects who donated either 400 ml whole blood within 16 weeks, 200 ml whole blood within 4 weeks, or blood components within 2 weeks, prior to the current study. 15. Pregnant or lactating women or women who expect to be pregnant during this study. 16. Subjects who currently participate in other clinical trials, or participated within the last 4 weeks prior to the current study. 17. Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Defecation frequency after 2 weeks of ingestion. | — |
Secondary
| Measure | Time frame |
|---|---|
| Stoolvolume, stool shape, stool color, stool odor, feeling after defecation, gut flora, heart rate variability, Electroencephalogram during sleeping, fecalmetabolome, blood metabolome, sleeping record (physical conditions before and after sleeping) | — |
Countries
Japan
Contacts
Public ContactJun NISHIHIRA
Hokkaido Information University Health Information Science Center
Outcome results
None listed